{"id":9720,"date":"2020-06-18T18:32:50","date_gmt":"2020-06-18T13:02:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9720"},"modified":"2023-02-10T12:10:56","modified_gmt":"2023-02-10T06:40:56","slug":"recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics","title":{"rendered":"Lassen\u2019s anti-IL-11 antibody; PTC\u2019s COVID-19 trial; Lenzilumab&#8217;s result; Orca raises $192M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fad54e5dd78\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fad54e5dd78\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics\/#Lassen_Therapeutics_to_create_anti-IL-11_antibody_for_cancer_and_fibrosis\" >Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics\/#PTC_Therapeutics_taps_cancer_drug_for_new_COVID-19_trial\" >PTC Therapeutics taps cancer drug for new COVID-19 trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics\/#Humanigen_shows_early_promise_in_COVID-19\" >Humanigen shows early promise in COVID-19<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics\/#Orca_Bio_violates_the_surface_with_USD_192_Million_for_high_precision_cell_therapies\" >Orca Bio violates the surface with USD 192 Million for high precision cell therapies<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-lassen-therapeutics-to-create-anti-il-11-antibody-for-cancer-and-fibrosis\"><span class=\"ez-toc-section\" id=\"Lassen_Therapeutics_to_create_anti-IL-11_antibody_for_cancer_and_fibrosis\"><\/span><strong>Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and Longwood Fund and has an aim to create antibodies for cancer and fibrosis treatment. IL-11, a cytokine that plays a role in both disease areas.<\/p>\n\n\n\n<p>Unlike antibody giant Regeneron, which had to set up its antibody generation platforms, Lassen and its team of seasoned antibody developers are leveraging the platforms developed by others to search and develop antibodies against new targets.<\/p>\n\n\n\n<p>Its initial plan was to create an antibody against IL-11 using those external platforms, but it found out that Australia\u2019s CSL had several patents and molecules around that cytokine.<\/p>\n\n\n\n<p>Blocking IL-11 could be even more effective than blocking other fibrosis-driving cytokines like TGF-beta. That is due to proteins like TGF-beta and CTGF all feed into a common pathway, IL-11, making it an \u201cattractive focal point of profibrotic factors.<\/p>\n\n\n\n<p>Lassen is primarily interested in fibrosis of the lung and liver. It is still pondering over which specific cancer indications it wants to pursue, but <strong>breast<\/strong>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\"><strong>lung <\/strong><\/a>and <a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\"><strong>pancreatic cancers<\/strong><\/a> could all be potential targets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ptc-therapeutics-taps-cancer-drug-for-new-covid-19-trial\"><span class=\"ez-toc-section\" id=\"PTC_Therapeutics_taps_cancer_drug_for_new_COVID-19_trial\"><\/span><strong>PTC Therapeutics taps cancer drug for new COVID-19 trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>PTC Therapeutics is tapping a potential reworked pipeline med against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19.<\/strong><\/a> The biopharma has been concentrating on rare diseases, is tapping its early-stage cancer drug, presently in a test for certain leukaemias, to check if it can help patients afflicted with the disease.<\/p>\n\n\n\n<p>It is kick-starting a phase 2\/3 trial of PTC299, a small oral molecule that prevents the cellular enzyme dihydroorotate dehydrogenase (DHODH), in the anticipation that it can reduce viral replication and uncontrolled inflammatory response.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The randomized, double-blind, placebo-controlled study will be in two stages and is set to commence in the U.S. soon.<\/p>\n\n\n\n<p>The first stage of the test is comprising of 40 patients, followed by a larger cohort of around 340 patients. The primary aim is to evaluate how well PTC299 works compared with placebo as measured by time to respiratory improvement in adults hospitalized with COVID-19.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-humanigen-shows-early-promise-in-covid-19\"><span class=\"ez-toc-section\" id=\"Humanigen_shows_early_promise_in_COVID-19\"><\/span><strong>Humanigen shows early promise in COVID-19<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although infection with the novel coronavirus can result in severe pneumonia, most deaths associated with <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>COVID-19<\/strong><\/a> are due to a complication called a cytokine storm, an immune overreaction marked by the activation and release of large numbers of inflammatory molecules, which can harm the lungs.<\/p>\n\n\n\n<p>Among the many drugmakers focusing to address the syndrome to achieve better <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\"><strong>COVID-19<\/strong><\/a> results is Humanigen, a company run by Martin Shkreli. The company is reporting promising data from a study of its experimental drug lenzilumab in a small group of coronavirus patients, who received it on a compassionate-use basis.<\/p>\n\n\n\n<p>The treatment with lenzilumab helped patients with severe and critical COVID-19 pneumonia recover after a median of five days in the 12-patient study and published on the medRxiv. That was a lot faster than the 10- and 11-day recovery time with remdesivir of Gilead Sciences\u2014the only drug with an FDA emergency authorization in <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\"><strong>COVID-19<\/strong><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-orca-bio-violates-the-surface-with-usd-192-million-for-high-precision-cell-therapies\"><span class=\"ez-toc-section\" id=\"Orca_Bio_violates_the_surface_with_USD_192_Million_for_high_precision_cell_therapies\"><\/span><strong>Orca Bio violates the surface with USD 192 Million for high precision cell therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Bone marrow transplants can save the lives of patients by giving them a new immune system to combat cancer. However, life-threatening side effects can also occur. Hence their use is put down to the sickest of patients. Orca Bio intends to change by aiming how these treatments are made.<\/p>\n\n\n\n<p>The Bay Area biotech is coming out of secrecy with a USD 192 million series D round that will drive a pipeline of high precision allogeneic cell therapies and the manufacturing technology behind those treatments. Orca Bio, founded in 2016, zeroed in on manufacturing to create bone marrow transplants safer and more effective.<\/p>\n\n\n\n<p>There is a bit of a compromise &#8211; One can have precision and a few cells, or can have lots of cells and sacrifice precision. Many people deal with less precision in order to get the sheer number of cells to treat patients, but they focused on technology to process extremely large numbers of cells while still having single-cell precision.<\/p>\n\n\n\n<p>Orca proposes to take donor T cells and stem cells, classify them into their different subtypes and join them in the right mixture for disease treatment.<\/p>\n\n\n\n<p>They do not genetically modify. However, if they take these cells and build a proprietary mix of them with single-cell precision, they can define the function- as stated by Dimov, Orca CEO and co-founder.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and Longwood Fund and has an aim to create antibodies for cancer and fibrosis treatment. IL-11, a cytokine that plays a role in both disease areas. Unlike antibody giant Regeneron, which had [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9725,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":3,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[127,18476,18474,349,365,18477,449,639,18475],"industry":[17225],"therapeutic_areas":[17228,17411],"class_list":["post-9720","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-breast-cancer","tag-humanigen","tag-lassen-therapeutics","tag-latest-pharma-news","tag-lung-cancer","tag-orca-bio","tag-pancreatic-cancer","tag-pharma-news","tag-ptc-therapeutics","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Lassen Therapeutics, PTC Therapeutics, Orca Bio<\/title>\n<meta name=\"description\" content=\"Lassen\u2019s anti-IL-11 antibody; PTC Therapeutics&#039;s COVID-19 trial; Humanigen shows early promise in COVID-19; Orca raises $192M\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Lassen Therapeutics, PTC Therapeutics, Orca Bio\" \/>\n<meta property=\"og:description\" content=\"Lassen\u2019s anti-IL-11 antibody; PTC Therapeutics&#039;s COVID-19 trial; Humanigen shows early promise in COVID-19; Orca raises $192M\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-18T13:02:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:40:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/18183148\/news-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Lassen Therapeutics, PTC Therapeutics, Orca Bio","description":"Lassen\u2019s anti-IL-11 antibody; PTC Therapeutics's COVID-19 trial; Humanigen shows early promise in COVID-19; Orca raises $192M","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Lassen Therapeutics, PTC Therapeutics, Orca Bio","og_description":"Lassen\u2019s anti-IL-11 antibody; PTC Therapeutics's COVID-19 trial; Humanigen shows early promise in COVID-19; Orca raises $192M","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-18T13:02:50+00:00","article_modified_time":"2023-02-10T06:40:56+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/18183148\/news-3.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics","name":"Pharma News | Lassen Therapeutics, PTC Therapeutics, Orca Bio","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/18183148\/news-3.jpg","datePublished":"2020-06-18T13:02:50+00:00","dateModified":"2023-02-10T06:40:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Lassen\u2019s anti-IL-11 antibody; PTC Therapeutics's COVID-19 trial; Humanigen shows early promise in COVID-19; Orca raises $192M","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-humanigen-orca-lassen-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/18183148\/news-3.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/18183148\/news-3.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/18183148\/news-3-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Humanigen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lassen Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lung Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orca Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PTC Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Humanigen<\/span>","<span class=\"advgb-post-tax-term\">Lassen Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Lung Cancer<\/span>","<span class=\"advgb-post-tax-term\">Orca Bio<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">PTC Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 18, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Jun 18, 2020 6:32 pm","modified":"Updated on Feb 10, 2023 12:10 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9720"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9720\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9725"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9720"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9720"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}